Manfred Hauben|Robert F. Reynolds|Patrick Caubel
Deconstructing the Pharmacovigilance Hype Cycle
Pfizer (United States)|Pfizer (United States)|Pfizer (United States)
data science making increasing contributions pharmacovigilance although technical innovation works indisputable efficient progress realworld pharmacovigilance signal detection may hampered corresponding technology life cycle effects resulting tendency conclude large enough datasets intricate algorithms numbers speak discounting importance clinical scientific judgment practical consequence overzealous declarations regarding safety lack safety drugs describe concerns critical discussion key results conclusions case studies selected illustrate points